

For Immediate Release

August 20, 2025

EXORPHIA and ROHTO Pharmaceutical Enter into Strategic Alliance to Advance Extracellular Vesicle Production Technology

Collaboration combines complementary strengths in regenerative medicine

Tokyo, Japan – August 20, 2025

EXORPHIA Inc. (Headquarters: Tokyo; CEO: Koji Kuchiishi, “EXORPHIA”) today announced that it has signed a business collaboration agreement with ROHTO Pharmaceutical Co., Ltd. (Headquarters: Osaka; President: Hidetoshi Segi, “ROHTO”), following the capital alliance previously established between the two companies. The collaboration will focus on the development of production technologies for extracellular vesicles (EVs), which include exosomes.

Background and Purpose

EXORPHIA is a biotechnology start-up pioneering novel therapeutics based on extracellular vesicles (EVs). Since its founding in 2019, the company has advanced product development across multiple disease areas, with the mission of transforming healthcare through EV science.

Rohto has established the “Rohto Group Comprehensive Management Vision 2030: Connect for Well-being” and is continuing to take on various challenges toward the future of medical care and healthcare with the aim of realizing a well-being society. In the regenerative medicine business, the company is conducting research and development centered on mesenchymal stromal cells (MSCs).

Through this collaboration, ROHTO’s manufacturing infrastructure and quality management systems will be combined with EXORPHIA’s proprietary EV production and development expertise. Together, the companies will advance EV production technologies with the aim of expanding opportunities in regenerative medicine and enhancing corporate value.

Outlook

The financial impact of this collaboration on ROHTO's consolidated results for the fiscal year ending March 2026 is expected to be minimal. Any material updates will be disclosed promptly.

Company Profiles

EXORPHIA Inc.

- Headquarters: Chiyoda-ku, Tokyo
- Founded: 2019
- CEO: Koji Kuchiishi
- Business: Development, manufacturing, and commercialization of EV-based therapeutics and high-value additives (e.g., IVF reagents)
- Website: <https://exorphia.com/en>

ROHTO Pharmaceutical Co., Ltd.

- Headquarters: Osaka, Japan
 - Founded: 1949
 - President: Hidetoshi Segi
 - Business: OTC pharmaceuticals, skincare, functional foods, medical ophthalmology, regenerative medicine, and CDMO services
 - Website: <https://www.rohto.com>
-

Media Contacts

EXORPHIA Inc. – Public Relations

Email: inquiry@exorphia.com

ROHTO Pharmaceutical Co., Ltd. – Public Relations & CSV Promotion Dept.

Email: pr@rohto.co.jp

Osaka Office: Tel +81-6-6758-1211 | Fax +81-6-6758-9820

Tokyo Office: Tel +81-3-5442-6074 | Fax +81-3-6832-6006